BR112018001387A2 - composição de absorção percutânea, e, agente para promover a absorbabilidade transdérmica de um medicamento básico - Google Patents

composição de absorção percutânea, e, agente para promover a absorbabilidade transdérmica de um medicamento básico

Info

Publication number
BR112018001387A2
BR112018001387A2 BR112018001387-0A BR112018001387A BR112018001387A2 BR 112018001387 A2 BR112018001387 A2 BR 112018001387A2 BR 112018001387 A BR112018001387 A BR 112018001387A BR 112018001387 A2 BR112018001387 A2 BR 112018001387A2
Authority
BR
Brazil
Prior art keywords
basic
promote
absorption composition
agent
percutaneous absorption
Prior art date
Application number
BR112018001387-0A
Other languages
English (en)
Japanese (ja)
Other versions
BR112018001387B1 (pt
BR112018001387B8 (pt
Inventor
Miwa Yasushi
Hamamoto Hidetoshi
Akazama Naoya
Original Assignee
Medrx Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medrx Co., Ltd. filed Critical Medrx Co., Ltd.
Publication of BR112018001387A2 publication Critical patent/BR112018001387A2/pt
Publication of BR112018001387B1 publication Critical patent/BR112018001387B1/pt
Publication of BR112018001387B8 publication Critical patent/BR112018001387B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

o objetivo da presente invenção é fornecer: uma composição de absorção transdérmica tendo propriedades melhoradas de penetração do fármaco básico na pele; e um acelerador de absorção transdérmica para um fármaco básico. o objetivo pode ser alcançado por uma composição de absorção transdérmica compreendendo um fármaco básico ou um sal do mesmo e ácido sórbico e/ou um sal metálico de ácido sórbico. é preferido que o teor do componente de ácido sórbico seja de 0,5 a 2,5 mols com relação a 1 mol do fármaco básico. também é preferido que a composição de acordo com a presente invenção contenha adicionalmente um composto básico orgânico e/ou um componente básico inorgânico.
BR112018001387A 2015-08-29 2016-08-29 Composição de absorção percutânea, e, emplastro tipo matriz BR112018001387B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/JP2015/074553 WO2017037813A1 (ja) 2015-08-29 2015-08-29 塩基性薬物とソルビン酸とを含有する経皮吸収組成物
JPPCT/JP2015/074553 2015-08-29
PCT/JP2016/075203 WO2017038767A1 (ja) 2015-08-29 2016-08-29 経皮吸収組成物

Publications (3)

Publication Number Publication Date
BR112018001387A2 true BR112018001387A2 (pt) 2018-09-11
BR112018001387B1 BR112018001387B1 (pt) 2023-09-05
BR112018001387B8 BR112018001387B8 (pt) 2024-03-05

Family

ID=58187853

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001387A BR112018001387B8 (pt) 2015-08-29 2016-08-29 Composição de absorção percutânea, e, emplastro tipo matriz

Country Status (15)

Country Link
EP (1) EP3342423B1 (pt)
JP (2) JP6259117B2 (pt)
KR (1) KR20180039622A (pt)
CN (1) CN107427509B (pt)
BR (1) BR112018001387B8 (pt)
CO (1) CO2018001831A2 (pt)
ES (1) ES2864017T3 (pt)
MX (1) MX2018002015A (pt)
MY (1) MY189987A (pt)
PH (1) PH12018500271A1 (pt)
RU (1) RU2702356C2 (pt)
SG (1) SG11201800043UA (pt)
UA (1) UA123212C2 (pt)
WO (2) WO2017037813A1 (pt)
ZA (1) ZA201800296B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2968551T3 (es) 2018-01-31 2024-05-10 Medrx Co Ltd Sistema terapéutico de tizanidina
CN118103036A (zh) * 2021-10-15 2024-05-28 Lts罗曼治疗系统股份公司 用于透皮施用替扎尼定的透皮治疗系统

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61172830A (ja) * 1985-01-26 1986-08-04 Showa Denko Kk 皮膚外用剤組成物
US20040142024A1 (en) * 1999-07-27 2004-07-22 Hisamitsu Pharmaceutical Co., Inc. Patch formulation for external use
CN1222281C (zh) * 1999-07-27 2005-10-12 久光制药株式会社 外用贴剂
RU2334507C2 (ru) * 2004-03-19 2008-09-27 Макнейл Аб Средство для чрескожного введения никотина
JP4807974B2 (ja) * 2005-06-30 2011-11-02 帝國製薬株式会社 経皮吸収促進組成物
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
CN101143127A (zh) * 2007-10-25 2008-03-19 复旦大学 一种酚妥拉明外用制剂及其制备方法
EP2223703A4 (en) * 2007-11-22 2011-01-19 Medrx Co Ltd EXTERNAL PREPARATION COMPOSITION COMPRISING FATTY ACID-BASED IONIC LIQUID AS ACTIVE INGREDIENT
ES2536206T3 (es) * 2008-02-27 2015-05-21 Hisamitsu Pharmaceutical Co., Inc. Parche medicinal
JP2012158521A (ja) * 2009-04-17 2012-08-23 Kureha Corp 外用剤
WO2011027786A1 (ja) * 2009-09-07 2011-03-10 ニプロパッチ株式会社 経皮吸収型製剤
CN102858321A (zh) * 2010-06-18 2013-01-02 莫茨药物股份两合公司 用于局部使用1-氨基-烷基环己烷衍生物的凝胶制剂
TR201911328T4 (tr) * 2012-06-20 2019-08-21 Medrx Co Ltd İlaç, organik çözücü, lipofilik merhem bazı ve tozun harmanlanmasıyla elde edilen yapıştırıcı preparasyon bileşimi.

Also Published As

Publication number Publication date
RU2702356C2 (ru) 2019-10-08
EP3342423B1 (en) 2021-03-10
ZA201800296B (en) 2019-04-24
JP2017149782A (ja) 2017-08-31
RU2018110617A (ru) 2019-09-30
BR112018001387B1 (pt) 2023-09-05
CN107427509B (zh) 2021-06-15
BR112018001387B8 (pt) 2024-03-05
JPWO2017038767A1 (ja) 2017-09-07
CO2018001831A2 (es) 2018-05-21
UA123212C2 (uk) 2021-03-03
RU2018110617A3 (pt) 2019-09-30
PH12018500271A1 (en) 2018-08-13
WO2017037813A1 (ja) 2017-03-09
ES2864017T3 (es) 2021-10-13
MX2018002015A (es) 2018-06-19
JP6259117B2 (ja) 2018-01-10
CN107427509A (zh) 2017-12-01
KR20180039622A (ko) 2018-04-18
SG11201800043UA (en) 2018-02-27
WO2017038767A1 (ja) 2017-03-09
EP3342423A1 (en) 2018-07-04
MY189987A (en) 2022-03-22
EP3342423A4 (en) 2018-07-25

Similar Documents

Publication Publication Date Title
BR112015029144A2 (pt) formulações de gel para guiar radioterapia
BR112016002171A2 (pt) método, composição estéril e injetável e método para preparar uma composição estéril e injetável
BR112017012327A8 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
BR112017009252A2 (pt) solução de nicotina, sistema eletrônico de fornecimento de vapor, processo para melhorar as propriedades sensoriais de uma solução de nicotina vaporizada e uso de um ou mais ácidos
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
BR112019006955A2 (pt) métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
BR112016013299A2 (pt) Composto
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
BR112017003433A2 (pt) inibidores espirocíclicos de catepsina c
BR112018003232A2 (pt) terapias de combinação para tratamento de câncer
BR112016021648A2 (pt) novos compostos
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
BR112015029367A2 (pt) terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas
BR112015020990A2 (pt) imidazopiridazinas substituídas
BR112013028786A2 (pt) método e composição de tratamento de sementes
CO2017005201A2 (es) Ácido benzóico, derivados de ácido benzóico y conjugados heteroarilcarboxílico de la oxicodona
BR112018002520A2 (pt) Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
BR112015026631A2 (pt) compostos ou sais farmaceuticamente aceitáveis dos mesmos e respectivos usos, composição farmacêutica e método para prevenir ou tratar diabetes melito em mamífero
BR112018015851A2 (pt) composto, e, medicamento.
BR112018012765A2 (pt) composição, método para tratamento, prevenção e/ou melhora de uma afecção médica, e, dispositivo mecânico.
BR112018001387A2 (pt) composição de absorção percutânea, e, agente para promover a absorbabilidade transdérmica de um medicamento básico
BRPI0713743C1 (pt) composto, e, composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/08/2016, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2748 DE 05/09/2023, QUANTO AO ITEM (72) NOME DO INVENTOR.